IP Library Granted Patent US 7,989,186
Granted Patent B2
US 7,989,186 · App. 12/214,317 · Granted Aug 2, 2011

Compositions and methods for detecting cryptococcus neoformans

Assignee: Medical Diagnostic Laboratories, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,989,186
App. No.
12/214,317
Granted
Aug 2, 2011
Kind
B2
Abstract

Disclosed are oligonucleotides useful in methods for determining whether a sample contains Cryptococcus neoformans , a causative agent for human cryptococcosis. These oligonucleotides, which have nucleotide sequences derived from a coding segment of the gene encoding the fungal specific transcription factor gene in Cryptococcus neoformans , are useful as forward and reverse primers for a polymerase chain reaction using nucleic acids from a biological sample as templates, and as probes for detecting any resultant amplicon. Detection of an amplicon indicates the sample contains Cryptococcus neoformans . Real-time PCR and detection using florescence resonance energy transfer is disclosed.

Claims (19)

1. A method of detecting presence of Cryptococcus neoformans in a biological sample, comprising:

(a) mixing

(i) DNA extracted from said biological sample,

(ii) a primer pair comprising a forward primer and a reverse primer that target a fungal specific transcription factor gene of Cryptococcus neoformans , and

(iii) a hybridization probe, in a PCR vessel, wherein said hybridization probe comprises a fluorescent moiety;

(b) amplifying, in a real-time PCR reaction, under conditions to allow production of an amplicon; and

(c) detecting a presence or absence of Cryptococcus neoformans , by detecting a presence or absence of a fluorescent signal resulting from the formation of said amplicon, wherein the presence of a fluorescent signal is indicative of the presence of Cryptococcus neoformans.

2. The method of claim 1 , wherein said forward primer consists essentially of nucleotide sequence 1121-1144 set forth in SEQ ID NO: 1, nucleotide sequence 1480-1499, or nucleotide sequence 2105-2124 set forth in SEQ ID NO: 1, said reverse primer consists essentially of nucleotide sequence 1512-1533 set forth in SEQ ID NO: 2, nucleotide sequence 1165-1184, or nucleotide sequence 508-527 set forth in SEQ ID NO: 2, and said hybridization probe consists essentially of nucleotide sequence 1150-1178 of SEQ ID NO: 1 or nucleotide sequence 1583-1611 of SEQ ID NO: 2.

3. The method of claim 2 , wherein said forward primer has at least 99% identity to a nucleotide sequence 1121-1144 set forth in SEQ ID NO: 1, nucleotide sequence 1480-1499 set forth in SEQ ID NO: 1, or nucleotide sequence 2105-2124 set forth in SEQ ID NO: 1, said reverse primer has at least 99% identity to a nucleotide sequence 1512-1533 set forth in SEQ ID NO: 2, nucleotide sequence 1165-1184 set forth in SEQ ID NO: 2, or nucleotide sequence 508-527 set forth in SEQ ID NO: 2, and said hybridization probe has at least 99% identity to a nucleotide sequence 1150-1178 of SEQ ID NO: 1 or nucleotide sequence 1583-1611 of SEQ ID NO: 2.

4. The method of claim 2 , wherein said forward primer has at least 95% identity to a nucleotide sequence 1121-1144 set forth in SEQ ID NO: 1, nucleotide sequence 1480-1499 set forth in SEQ ID NO: 1, or nucleotide sequence 2105-2124 set forth in SEQ ID NO: 1, said reverse primer has at least 95% identity to a nucleotide sequence 1512-1533 set forth in SEQ ID NO: 2, nucleotide sequence 1165-1184 set forth in SEQ ID NO: 2, or nucleotide sequence 508-527 set forth in SEQ ID NO: 2, and said hybridization probe has at least 95% identity to a nucleotide sequence 1150-1178 of SEQ ID NO: 1 or nucleotide sequence 1583-1611 of SEQ ID NO: 2.

5. The method of claim 2 , wherein said forward primer has at least 90% identity to a nucleotide sequence 1121-1144 set forth in SEQ ID NO: 1, nucleotide sequence 1480-1499 set forth in SEQ ID NO: 1, or nucleotide sequence 2105-2124 set forth in SEQ ID NO: 1, said reverse primer has at least 90% identity to a nucleotide sequence 1512-1533 set forth in SEQ ID NO: 2, nucleotide sequence 1165-1184 set forth in SEQ ID NO: 2, or nucleotide sequence 508-527 set forth in SEQ ID NO: 2, and said hybridization probe has at least 90% identity to a nucleotide sequence 1150-1178 of SEQ ID NO: 1 or nucleotide sequence 1583-1611 of SEQ ID NO: 2.

6. The method of claim 1 , wherein said forward primer has a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6, SEQ ID NO: 8, and said reverse primer has a nucleotide sequence selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 7, and SEQ ID NO: 9.

7. The method of claim 1 , wherein said fluorescein moiety is 6-carboxy-fluorescein.

8. A method of detecting presence of Cryptococcus neoformans in a biological sample, comprising:

(a) mixing

(i) DNA extracted from said biological sample, and

(ii) a primer pair comprising a forward primer and a reverse primer that target a fungal specific transcription factor gene of Cryptococcus neoformans;

(b) amplifying, in a PCR reaction, under conditions to allow production of an amplicon; and

(c) detecting a presence or absence of Cryptococcus neoformans in said sample.

Assignments (5)
SECURITY INTEREST Recorded Jul 13, 2022
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 060638/0353 →
RELEASE OF SECURITY INTEREST Recorded Jun 12, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: MEDICAL DIAGNOSTIC LABORATORIES L. L. C.
Reel/Frame 046354/0817 →
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
SECURITY INTEREST Recorded Mar 1, 2016
From: MEDICAL DIAGNOTIC LABORATORIES, L.L.C.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 037963/0744 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2009
From: FEOLA, MELANIE; ADELSON, MARTIN; MORDECHAI, ELI; ENTWISTLE, JOHN
To: MEDICAL DIAGNOSTIC LABORATORIES, LLC
Reel/Frame 023563/0047 →
Continuity (2)
Provisional Application 60936628 · Jun 20, 2007
Related Publication 20090246767A1 · Oct 1, 2009